Emyria's PTSD Program Delivers Lasting Recovery

Emyria has released clinically significant 12+ month follow-up data from its PTSD treatment program, demonstrating durable remission in a severe, treatment-resistant cohort. 

Key findings include: 

• Two-thirds of patients in clinical remission 12 months post treatment. PTSD symptom scores remain below the diagnostic clinical threshold (remission) 12+ months posttreatment, evidence of sustained relief 

• Median recovery time ~1 month. 50% of patients reach remission within 28 days of the start of treatment, a further ~16% reach remission during the follow-up period. 

• Routine safety monitoring during follow-up did not identify any severe adverse reactions or safety concerns. 

These outcomes are drawn from real-world clinical services delivered under Australia’s regulated access pathways and build on the positive six-month data we shared last year. 

PTSD affects approximately 1 in 11 Australians during their lifetime, with high levels of treatment resistance and drop-out rates under conventional approaches. Durable remission has implications not only for patient outcomes, but also for long-term cost-of-care and reimbursement confidence. 

Executive Chair Greg Hutchinson:  
"That the majority of patients undergoing Emyria’s treatments are achieving durable and often immediate benefit is impactful, not just for the patient, but also for their families and friends. It’s also important to other stakeholders in the mental healthcare system, from practitioners who are witnessing previously inaccessible results, to payers seeking more cost-effective options. 

“We're building a data-driven platform that is driving practitioner and patient acquisition, and sustainable geographic growth across a nation-wide clinic network.” 

Read the ASX release